Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 19;4(3):98.
doi: 10.3390/jof4030098.

Treatment of Aspergillosis

Affiliations
Free PMC article
Review

Treatment of Aspergillosis

Jeffrey D Jenks et al. J Fungi (Basel). .
Free PMC article

Abstract

Infections caused by Aspergillus spp. remain associated with high morbidity and mortality. While mold-active antifungal prophylaxis has led to a decrease of occurrence of invasive aspergillosis (IA) in those patients most at risk for infection, breakthrough IA does occur and remains difficult to diagnose due to low sensitivities of mycological tests for IA. IA is also increasingly observed in other non-neutropenic patient groups, where clinical presentation is atypical and diagnosis remains challenging. Early and targeted systemic antifungal treatment remains the most important predictive factor for a successful outcome in immunocompromised individuals. Recent guidelines recommend voriconazole and/or isavuconazole for the primary treatment of IA, with liposomal amphotericin B being the first alternative, and posaconazole, as well as echinocandins, primarily recommended for salvage treatment. Few studies have evaluated treatment options for chronic pulmonary aspergillosis (CPA), where long-term oral itraconazole or voriconazole remain the treatment of choice.

Keywords: Aspergillus; amphotericin; chronic pulmonary aspergillosis; diagnosis; interleukin 8; invasive aspergillosis; isavuconazole; itraconzole; posaconazole; voriconazole.

Conflict of interest statement

J.D.J. has no conflict. M.H. has received untied research funding from Gilead and speaker’s honoraria from Merck, Basilea, and Gilead.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Alastruey-Izquierdo A., Cadranel J., Flick H., Godet C., Hennequin C., Hoenigl M., Kosmidis C., Lange C., Munteanu O., Page I., et al. Treatment of chronic pulmonary aspergillosis: Current standards and future perspectives. Respiration. 2018;6:1–12. doi: 10.1159/000489474. - DOI - PubMed
    1. Denning D.W., Page I.D., Chakaya J., Jabeen K., Jude C.M., Cornet M., Alastruey-Izquierdo A., Bongomin F., Bowyer P., Chakrabarti A., et al. Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerg. Infect. Dis. 2018;24:e171312. doi: 10.3201/eid2408.171312. - DOI - PMC - PubMed
    1. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., Ito J., Andes D.R., Baddley J.W., Brown J.M., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) Database. Clin. Infect. Dis. 2010;50:1091–1100. doi: 10.1086/651263. - DOI - PubMed
    1. Cornely O.A., Lass-Florl C., Lagrou K., Arsic-Arsenijevic V., Hoenigl M. Improving outcome of fungal diseases-Guiding experts and patients towards excellence. Mycoses. 2017;60:420–425. doi: 10.1111/myc.12628. - DOI - PubMed
    1. Geiser D. Sexual structures in Aspergillus: Morphology, importance and genomics. Med. Mycol. 2009;47:S21–S26. doi: 10.1080/13693780802139859. - DOI - PubMed
Feedback